ES3029611T3 - Metabolites for treatment and prevention of autoimmune disease - Google Patents

Metabolites for treatment and prevention of autoimmune disease

Info

Publication number
ES3029611T3
ES3029611T3 ES17838221T ES17838221T ES3029611T3 ES 3029611 T3 ES3029611 T3 ES 3029611T3 ES 17838221 T ES17838221 T ES 17838221T ES 17838221 T ES17838221 T ES 17838221T ES 3029611 T3 ES3029611 T3 ES 3029611T3
Authority
ES
Spain
Prior art keywords
fatty acids
chain fatty
combination
nod
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17838221T
Other languages
English (en)
Spanish (es)
Inventor
Charles Reay Mackay
Eliana Marino Moreno
Trevor Lockett
Julie Clarke
David Topping
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organisation
Monash University
Original Assignee
Commonwealth Scientific and Industrial Research Organisation
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903143A external-priority patent/AU2016903143A0/en
Application filed by Commonwealth Scientific and Industrial Research Organisation, Monash University filed Critical Commonwealth Scientific and Industrial Research Organisation
Application granted granted Critical
Publication of ES3029611T3 publication Critical patent/ES3029611T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Pediatric Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES17838221T 2016-08-10 2017-08-10 Metabolites for treatment and prevention of autoimmune disease Active ES3029611T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016903143A AU2016903143A0 (en) 2016-08-10 Metabolites for treatment of autoimmune disease
PCT/AU2017/050845 WO2018027274A1 (en) 2016-08-10 2017-08-10 Metabolites for treatment and prevention of autoimmune disease

Publications (1)

Publication Number Publication Date
ES3029611T3 true ES3029611T3 (en) 2025-06-27

Family

ID=61160999

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17838221T Active ES3029611T3 (en) 2016-08-10 2017-08-10 Metabolites for treatment and prevention of autoimmune disease

Country Status (8)

Country Link
US (3) US20190167615A1 (enExample)
EP (1) EP3496708B1 (enExample)
JP (1) JP7097027B2 (enExample)
CN (1) CN109562088A (enExample)
AU (1) AU2017310263B2 (enExample)
CA (1) CA3070939A1 (enExample)
ES (1) ES3029611T3 (enExample)
WO (1) WO2018027274A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110475551A (zh) 2017-01-27 2019-11-19 英联邦高等教育系统天普大学 使用短链脂肪酸治疗和预防疾病和障碍
EP3863621A4 (en) * 2018-10-09 2022-08-24 Monash University COMBINATION THERAPY FOR THE TREATMENT AND PREVENTION OF AUTOIMMUNE AND INFLAMMATION DISEASES
CN109771404A (zh) * 2019-02-28 2019-05-21 北京大学人民医院(北京大学第二临床医学院) 丁酸在制备预防和/或治疗自身免疫性疾病药物中的应用
EP3838283A1 (en) * 2019-12-18 2021-06-23 Mundus Sanus GmbH & Co. KG Composition for use in the treatment of provocative diseases
JP7832125B2 (ja) 2020-06-03 2026-03-17 コーンプロダクツ ディベロップメント インコーポレーテッド Ｔｒｉ置換デンプンの組成物及びそれを作製及び使用する方法
JP2022092605A (ja) * 2020-12-10 2022-06-22 森下仁丹株式会社 経口固形製剤および経口組成物
CN115068458B (zh) * 2022-07-21 2023-12-12 哈尔滨医科大学 戊酸在制备防治糖尿病药物中的应用
WO2026060366A1 (en) * 2024-09-13 2026-03-19 Temple University-Of The Commonwealth System Of Higher Education Short chain fatty acid compounds and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039703A (en) * 1989-11-16 1991-08-13 Breuer Richard I Method for treating inflammatory bowel disorders
CA2176719C (en) * 1993-11-17 2007-09-18 Geoffrey Anisson Fatty acid delivery system
AUPQ132599A0 (en) * 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
DE102005046237A1 (de) * 2005-09-28 2007-04-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
US9693977B2 (en) * 2013-03-15 2017-07-04 President And Fellows Of Harvard College Method of increasing the quantity of colonic T regulatory cells via G-coupled protein receptor 43
US20160271086A1 (en) * 2013-10-31 2016-09-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for inducing regulatory t-cell generation
US10226443B2 (en) * 2014-10-16 2019-03-12 New York University Methods for treating psoriatic arthritis
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
CN110475551A (zh) * 2017-01-27 2019-11-19 英联邦高等教育系统天普大学 使用短链脂肪酸治疗和预防疾病和障碍
EP3863621A4 (en) * 2018-10-09 2022-08-24 Monash University COMBINATION THERAPY FOR THE TREATMENT AND PREVENTION OF AUTOIMMUNE AND INFLAMMATION DISEASES

Also Published As

Publication number Publication date
JP2019527714A (ja) 2019-10-03
US20250295617A1 (en) 2025-09-25
EP3496708B1 (en) 2025-03-26
AU2017310263A1 (en) 2019-02-07
AU2017310263B2 (en) 2023-08-10
US20210244692A1 (en) 2021-08-12
CA3070939A1 (en) 2018-02-15
CN109562088A (zh) 2019-04-02
EP3496708A4 (en) 2020-04-01
WO2018027274A1 (en) 2018-02-15
EP3496708C0 (en) 2025-03-26
US20190167615A1 (en) 2019-06-06
EP3496708A1 (en) 2019-06-19
JP7097027B2 (ja) 2022-07-07

Similar Documents

Publication Publication Date Title
US20250295617A1 (en) Metabolites for treatment and prevention of autoimmune disease
JP7688360B2 (ja) 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
Jamwal et al. Intestinal epithelial expression of MHCII determines severity of chemical, T-cell–induced, and infectious colitis in mice
ES2610146T3 (es) Composición para inducir la proliferación o acumulación de células T reguladoras
Kim et al. Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice
Martínez-Moya et al. Exogenous alkaline phosphatase treatment complements endogenous enzyme protection in colonic inflammation and reduces bacterial translocation in rats
Ren et al. Intestinal toxicity of metal nanoparticles: silver nanoparticles disorder the intestinal immune microenvironment
ES3061119T3 (en) Formulations for the treatment of neurodevelopmental deficiencies induced by necrotizing enterocolitis
CN110049760A (zh) 用于治疗炎性疾病的组合物及其用途以及益生菌组合物
CN102947441A (zh) 来自拟杆菌属的细胞组分、其组合物和使用拟杆菌或其细胞组分的治疗方法
ES2376493T3 (es) Procedimiento para reducir o aliviar la inflamación en el tubo digestivo.
CN105722504A (zh) 无定形的镁取代磷酸钙组合物及其用途
WO2017160944A2 (en) Compositions and methods for treating and preventing graft versus host disease
WO2020028871A1 (en) Prenatal probiotic formulations
KR20240093392A (ko) 질병 치료를 위한 조성물 및 방법
Han et al. Postbiotics ameliorate DSS-induced colitis in mice by regulating gut microbiota, promoting tryptophan metabolism, and activating AhR/IL-22 signaling pathway
Liu et al. Intestinal bacteria encapsulated by biomaterials enhance immunotherapy
US20220220202A1 (en) Combination therapy for treatment and prevention of autoimmune and inflammatory diseases
Hume et al. The pathogenesis of Crohn's disease in the 21st century
WO2024181919A1 (en) Milk-derived extracellular vesicles for gut barrier protection and therapeutic applications in gut barrier associated liver metabolic diseases and uses thereof
CN112770762A (zh) 制剂
JP2024534721A (ja) 人工酵素・細菌系及びその使用
Wang et al. Effect of microencapsulated Fiber2-displaying probiotics loaded with inulin nanoparticles on immunity against fowl adenovirus serotype 4 in chickens
Park et al. Inulin‐Butyrate Nanogel for Modulation of Gut Microbiome, Intestinal Barrier, and Regulatory T‐Cells in Colitis
Husseini et al. Investigating dietary microRNA stability and function using a transgenic milk model with unique microRNA sequences